The dual fatty acid amide hydrolase/TRPV1 blocker, N-arachidonoyl-serotonin, relieves carrageenan-induced inflammation and hyperalgesia in mice

Pharmacological Research

Volumn 61, Issue 6, 2010, Pages 537-546

  Costa, Barbara ^a   Bettoni, Isabella ^a   Petrosino, Stefania ^b   Comelli, Francesca ^a   Giagnoni, Gabriella ^a   Di Marzo, Vincenzo ^b  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b CNR   (Italy)

Author keywords

Cannabinoid; Capsazepine; FAAH; N arachidonoyl serotonin; TRPV1 receptor; URB597

Indexed keywords

ANANDAMIDE; CAPSAZEPINE; CARRAGEENAN; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; FATTY ACID AMIDASE INHIBITOR; N ARACHIDONOYL SEROTONIN; SEROTONIN AGONIST; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1 ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; ARTICLE; BODY TEMPERATURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; EDEMA; INFLAMMATION; LOCOMOTION; MALE; MOUSE; NONHUMAN; PAIN; PAW EDEMA; PRIORITY JOURNAL; SPINAL CORD DISEASE;

AMIDOHYDROLASES; ANALGESICS; ANIMALS; ANTI-INFLAMMATORY AGENTS; ARACHIDONIC ACIDS; BENZAMIDES; CAPSAICIN; CARBAMATES; CARRAGEENAN; HYPERALGESIA; INFLAMMATION; MICE; RECEPTOR, CANNABINOID, CB1; SEROTONIN; TRPV CATION CHANNELS;

EID: 77952885551     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2010.02.001     Document Type: Article

References (51)

1. Bisogno T., Melck D., De Petrocellis L., Bobrov M.Yu, Gretskaya N.M., Bezuglov V.V., et al. Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase. Biochem Biophys Res Commun 1998, 248:515-522.
2. Fowler C.J., Tiger G., Lopez-Rodriguez M.L., Viso A., Ortega-Gutierrez S., Ramos J.A. Inhibition of fatty acid amidohydrolase, the enzyme responsible for the metabolism of the endocannabinoid anandamide, by analogues of arachidonoyl-serotonin. J Enzyme Inhib Med Chem 2003, 18:225-231.
3. de Lago E., Petrosini S., Valenti M., Morera E., Ortega-Gutierrez S., Fernandez-Ruiz J., et al. Effect of repeated systemic administration of selective inhibitors of endocannabinoid inactivation on rat brain endocannabinoid levels. Biochem Pharmacol 2005, 70:446-452.
4. Suplita R.L., Farthing J.N., Gutierrez T., Hohmann A.G. Inhibition of fatty-acid amide hydrolase enhances cannabinoid stress-induced analgesia: sites of action in the dorsolateral periaqueductal grey and rostral ventromedial medulla. Neuropharmacology 2005, 49:1201-1209.
5. D'Argenio G., Valenti M., Scaglione G., Cosenza V., Sorrentini I., Di Marzo V. Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. FASEB J 2006, 20:568-570.
6. Ligresti A., Bisogno T., Matias I., De Petrocellis L., Cascio M.G., Cosenza V., et al. Possible endocannabinoid control of colorectal cancer growth. Gastroenterology 2003, 125:677-687.
7. Bifulco M., Laezza C., Valenti M., Ligresti A., Portella G., Di Marzo V. A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. FASEB J 2004, 18:1606-1608.
8. Maione S., De Petrocellis L., de Novellis V., Schiano Moriello A., Petrosino S., Palazzo E., et al. Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. Br J Pharmacol 2007, 150:766-781.
9. Lichtman A.H., Shelton C.C., Advani T., Cravatt B.F. Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. Pain 2004, 109:319-327.
10. Holt S., Comelli F., Costa B., Fowler C. Inhibitors of fatty acid amide hydrolase reduce carrageenan-induced hind paw inflammation in pentobarbital-treated mice: comparison with indomethacin and possibile involvement of cannabinoid receptors. Br J Pharmacol 2005, 146:467-476.
11. Jayamanne A., Greenwood R., Mitchell V.A., Aslan S., Piomelli D., Vaughan C.V. Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br J Pharmacol 2006, 147:281-288.
12. Jhaveri M.D., Richardson D., Kendall D.A., Barrett D.A., Chapman V. Analgesic effects of fatty acid amide hydrolase inhibition in a rat model of neuropathic pain. J Neurosci 2006, 26:13318-13327.
13. Davis J.B., Gray J., Gunthorpe M.J., Hatcher J.P., Davey P.T., Overend P., et al. Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature 2000, 405:183-187.
14. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983, 16:109-110.
15. Hargreaves K.M., Dubner R., Brown F., Flores C., Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 1988, 32:77-88.
16. Maione S., Bisogno T., de Novellis V., Palazzo E., Cristino L., Valenti M., et al. Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive payhways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type-1 receptors. J Pharmacol Exp Ther 2006, 316:969-982.
17. Compton D.R., Rice K.C., De Costa B.R., Razdan R.K., Melvin L.S., Johnson M.R., et al. Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J Pharmacol Exp Ther 1993, 265:218-226.
18. Pertwee R.G. The ring test: a quantitative method for assessing the cataleptic effect of cannabis in mice. Br J Pharmacol 1972, 46:753-763.
19. Comelli F., Giagnoni G., Bettoni I., Colleoni M., Costa B. The inhibition of monoacylglycerol lipase by URB602 showed an anti-inflammatory and anti-nociceptive effect in a murine model of acute inflammation. Br J Pharmacol 2007, 152:787-794.
20. Clayton N., Marshall F.H., Bountra C., O'Shaughnessy C.T. CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain. Pain 2002, 96:253-260.
21. Di Marzo V. The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation. Pharmacol Res 2009, 60:77-84.
22. Burstein S.H., Rossetti R.G., Yagen B., Zurier R.B. Oxidative metabolism of anandamide. Prostaglandins Other Lipid Mediat 2000, 61:29-41.
23. Sagar D.V., Gaw A.G., Okine B.N., Woodhams S.G., Wong A., Kendall D.A., et al. Dynamic regulation of the endocannabinoid system: implications for analgesia. Mol Pain 2009, 5:59-71.
24. Hu S.S., Bradshaw H.B., Chen J.S., Tan B., Walker J.M. Prostaglandin E2 glycerol ester, and endogenous COX-2 metabolite of 2-arachidonoylglycerol, induces hyperalgesia and modulates NFkappaB activity. Br J Pharmacol 2008, 153:1538-1549.
25. Di Marzo V., Maccarrone M. FAAH and anandamide: is 2-AG really the odd one out?. Trends Pharmacol Sci 2008, 29:229-233.
26. Maccarrone M., Rossi S., Bari M., De Chiara V., Fezza F., Musella A., et al. Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum. Nat Neurosci 2008, 11:152-159.
27. Caterina M.J., Leffler A., Malmberg A.B., Martin W.J., Trafton J., Petersen Z.K.R., et al. Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 2000, 288:306-313.
28. Kamei J., Zushida K., Morita K., Sasaki M., Tanaka S. Role of vanilloid VR1 receptor in thermal allodynia and hyperalgesia in diabetic mice. Eur J Pharmacol 2001, 422:83-86.
29. Walker K.M., Urban L., Medhurst S.J., Patel S., Panesar M., Fox A.J., et al. The VR1 antagonist capsazepine reverses mechanical hyperalgesia in models of inflammatory and neuropathic pain. J Pharmacol Exp Ther 2003, 304:56-62.
30. Gavva N.R., Treanor J.S., Garami A., Fang L., Surapaneni S., Akrami A., et al. Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans. Pain 2008, 136:202-210.
31. Kwak J.Y., Jung J.Y., Hwang S.W., Lee W.T., Oh U. A capsaicin-receptor antagonist, capsazepine, reduces inflammation-induced hyperalgesic responses in the rat: evidence for an endogenous capsaicin-like substance. Neuroscience 1998, 86:619-626.
32. Garcia-Martinez C., Fernandez-Carvajal A., Valenzuela B., Gomis A., Van Den Nest W., Ferroni, et al. Design and characterization of a noncompetitive antagonist of the transient receptor potential vanilloid subunit 1 channel with in vivo analgesic and anti-inflammatory activity. J Pain 2006, 7:735-746.
33. Jhaveri M.D., Richardson D., Robinson I., Garle M.J., Patel A., Sun Y., et al. Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases levels of endocannabinoid related molecules and produces analgesia via peroxisome proliferator-activated receptor-alpha in a model of inflammatory pain. Neuropharmacology 2008, 55:85-93.
34. Richardson J.D., Kilo S., Hargreaves K.M. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 1998, 75:111-119.
35. Niforatos W., Zhang X.F., Lake M.R., Walter K.A., Neelands T., Holzman T.F., et al. Activation of TRPA1 channels by the fatty acid amide hydrolase inhibitor 3'-carbamoylbiphenyl-3-yl cyclohexylcarbamate (URB597). Mol Pharmacol 2007, 71:1209-1216.
36. Gunthorpe M.J., Szallasi A. Peripheral TRPV1 receptors as targets for drug development: new molecules and mechanisms. Curr Pharm Des 2008, 14:32-41.
37. Holt S., Nilsson J., Omeir R., Tiger G., Fowler C.J. Effects of pH on the inhibition of fatty acid amidohydrolase by ibuprofen. Br J Pharmacol 2001, 133:513-520.
38. Olah Z., Karai L., Iadarola M.J. Anandamide activates vanilloid receptor 1 (VR1) at acidic pH in dorsal root ganglia neurons and cells ectopically expressing VR1. J Biol Chem 2001, 276:31163-31170.
39. Morgese M.G., Cassano T., Cuomo V., Giuffrida A. Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors. Exp Neurol 2007, 208:110-119.
40. Rubino T., Realini N., Castiglioni C., Guidali C., Viganò D., Marras E., et al. Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex. Cereb Cortex 2008, 18:1292-1301.
41. Foreman J.C., Jordan C.C., Oehme P., Renner H. Structure-activity relationships for some substance P-related peptides that cause wheal and flare reactions in human skin. J Physiol 1983, 335:449-465.
42. Brain S.D., Williams T.J., Tippings J.R., Morris H.R., MacIntyre I. Calcitonin gene-related peptide is a potent vasodilator. Nature 1985, 313:54-56.
43. Caterina M.J., Julius D. The vanilloid receptor: a molecular gateway to the pain pathway. Ann Rev Neurosci 2001, 24:487-517.
44. Southall M.D., Li T., Gharibova L.S., Pei Y., Nicol G.D., Travers J.B. Activation of epidermal vanilloid receptor-1 induces release of pro-inflammatory mediators in human keratinocytes. J Pharmacol Exp Ther 2003, 304:217-222.
45. Okajima K., Harada N. Regulation of inflammatory responses by sensory neurons: molecular mechanism(s) and possible therapeutic applications. Curr Med Chem 2006, 13:2241-2251.
46. Li W.H., Lee Y.M., Kim J.Y., Kang S., Kim S., Kim K.H., et al. Transient receptor potential vanilloid-1 mediates heat shock-induced matrix metalloproteinase-1 expression in human keratinocytes. J Invest Dermatol 2007, 127:2328-2335.
47. Tsuboi K., Sun Y.X., Okamoto Y., Araki N., Tonai T., Ueda N. Molecular characterization of N-acylethanolamine-hydrolyzing acid amidase, a novel member of the choloylglycine hydrolase family with structural and functional similarity to acid ceramidase. J Biol Chem 2005, 280:11082-11092.
48. Sun Y.X., Tsuboi K., Zhao L.Y., Okamoto Y., Lambert D.M., Ueda N. Involvement of N-acylethanolamine-hydrolyzing acid amidase in the degradation of anandamide and other N-acylethanolamines in macrophages. Biochim Biophys Acta 2005, 1736:211-220.
49. Weber A., Ni J., Ling K.H., Acheampong A., Tang-Liu D.D., Burk R., et al. Formation of prostamides from anandamide in FAAH knockout mice analyzed by HPLC with tandem mass spectrometry. J Lipid Res 2004, 45:757-763.
50. Ortar G., Cascio M.G., De Petrocellis L., Morera E., Rossi F., Schiano-Moriello A., et al. New N-arachidonoylserotonin analogues with potential " dual" mechanism of action against pain. J Med Chem 2007, 50:6554-6569.
51. De Novellis V., Palazzo E., Rossi F., De Petrocellis L., Petrosino S., Giuda F., et al. The analgesic effect of N-arachidonoyl-serotonin, a FAAH inhibitor and TRPV1 receptor antagonist, associated with changes in rostral ventromedial medulla and locus coeruleus cell activity in rats. Neuropharmacology 2008, 55:1105-1113.